Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma.
A third-generation fluoroquinolone, pradofloxacin (PRA), is currently being developed to treat bacterial infections in dogs. The purpose of this study was to assess the clinical efficacy in 20 dogs affected with superficial and deep pyoderma. An initial aerobic skin culture was performed in dogs with superficial pyoderma; aerobic/anaerobic tissue culture was performed in dogs with deep pyoderma; and skin cytology and biopsies were obtained from all dogs. Pradofloxacin (approximately 3 mg/kg per os [PO]) was administered daily to all dogs. Clinical efficacy was recorded at 4 weeks for dogs with superficial pyoderma and at 3 and 6 weeks for dogs with deep pyoderma. At a mean dosage of 3.7 mg/kg PO once daily, PRA treatment resulted in an excellent to good clinical response within 3 to 6 weeks for all 20 dogs with superficial and deep pyoderma.
Restrepo
Christina
C
Dermatology Service, School of Veterinary Medicine, University of California, Davis, California 95616-8747, USA.
Ihrke
Peter J
PJ
White
Stephen D
SD
Spiegel
Ian B
IB
Affolter
Verena K
VK
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D008297:Male; D011711:Pyoderma / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; C507250:pradofloxacin